Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. Provides Better Incubation Environment For Biotech Than Europe, Says Sanofi’s Viehbacher

Executive Summary

Taking the helm of EFPIA, Viehbacher says R&D and innovation are the keys to rescuing Europe from its economic slump, but more harmonization across the pharmaceutical sector will be needed too.

You may also be interested in...



Europe Renews Innovative Medicines Initiative, With Funding Boost

With a new budget of €3.4 billion over the next seven years, Europe’s public-private partnership in health aims to tackle difficult-to-treat neurodegenerative diseases and new antibiotics.

EU’s IMI, Drug Makers And Universities Join In New R&D Effort

Europe’s latest push to speed up new medicine discovery will see a new European Lead Factory set up under the EU’s Innovative Medicines Initiative, combining a library of up to 500,000 drug candidates from industry and academia and high-throughput screening centers to identify and generate new therapies.

GSK To Downplay Europe Because of Poor Innovation Support, Focuses On U.S. and Japan Instead

GSK CEO Andrew Witty is scathing about the lack of support in Europe for innovation, and the company will now prioritize the U.S., Japan and emerging markets for the development of new products

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS055449

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel